Clinical Trial

Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke

Study acronym: ARTS-MeVO
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Results from recent several trials provided data showing limits to the effectiveness of thrombectomy for ischemic stroke due to medium vessel occlusions.The benefit-risk profile of thrombolysis for these patients has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of tenecteplase (0.25mg/kg, maximum dose 25mg) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 4.5 to 24 hours from symptom onset.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-24; most recent amendment 2026-03-27.
Status change: Not Yet Recruiting → Recruiting 2025-08-01
Trial Details
NCT Number NCT07047014
Lead Sponsor Beijing Tiantan Hospital
Collaborators: First Affiliated Hospital of Zhejiang University, Chinese Stroke Association
Conditions Stroke, Ischemic, Medium Vessel Occlusions
Enrollment 596 participants
Start Date 2025-07-30
Primary Completion 2027-03-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-01